Incyte shares slip as PhII flop signals new problems ahead

Incyte ($INCY) took a nasty hit on its share price today after it reported that a combo study of Jakafi (ruxolitinib) and regorafinib (Bayer's Stivarga) failed a Phase II study on colorectal cancer. An interim analysis of the data concluded that the trial was a flop and analysts concluded that the risk of failure for pancreatic cancer, as well solid tumors in general, has gone up considerably. Incyte's shares dropped about 10% on the news. Not all analysts are so bearish, but in today's bear market for biotech stocks bad news is heavily amplified. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.